ANU Open Research Repository will be unavailable 8am-9am on Tuesday 13th August 2024 due to scheduled maintenance.
 

Quinoline Antimalarials Containing a Dibemethin Group are Active against Chloroquinone-Resistant Plasmodium falciparum and Inhibit Chloroquine Transport via the P. falciparum Chloroquine- Resistance Transporter (PfCRT)

Date

2011

Authors

Zishiri, Vincent K
Joshi, Mukesh C
Hunter, Roger
Chibale, Kelly
Smith, Peter J.
Summers, Robert
Martin, Rowena
Egan, Timothy J.

Journal Title

Journal ISSN

Volume Title

Publisher

American Chemical Society

Abstract

A series of 4-amino-7-chloroquinolines with dibenzylmethylamine (dibemethin) side chains were shown to inhibit synthetic hemozoin formation. These compounds were equally active against cultures of chloroquine-sensitive (D10) and chloroquine-resistant (K1) Plasmodium falciparum. The most active compound had an IC50 value comparable to that of chloroquine, and its potency was undiminished when tested in three additional chloroquine-resistant strains. The three most active compounds exhibited little or no cytotoxicity in a mammalian cell line. When tested in vivo against mouse malaria via oral administration, two of the dibemethin derivatives reduced parasitemia by over 99%, with mice treated at 100 mg/kg surviving the full length of the experiment. Three of the compounds were also shown to inhibit chloroquine transport via the parasite's chloroquine-resistance transporter (PfCRT) in a Xenopus oocyte expression system. This constitutes the first example of a dual-function antimalarial for which the ability to inhibit both hemozoin formation and PfCRT has been demonstrated directly.

Description

Keywords

Keywords: 4 amino 7 chloroquinoline derivative; antimalarial agent; chloroquine; dibemethin derivative; hemozoin; multidrug resistance protein; Plasmodium falciparum chloroquine resistance transporter; quinoline derivative; unclassified drug; animal experiment; ani

Citation

Source

Journal of Medicinal Chemistry

Type

Journal article

Book Title

Entity type

Access Statement

License Rights

DOI

10.1021/jm2009698

Restricted until

2037-12-31